JP Morgan Chase’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17M | Sell |
285,000
-523,800
| -65% | -$30.5M | ﹤0.01% | 2209 |
|
|
2025
Q4 | $43.6M | Sell |
808,800
-105,100
| -12% | -$5.06M | ﹤0.01% | 1450 |
|
|
2025
Q3 | $41.2M | Buy |
913,900
+760,700
| +497% | +$35.5M | ﹤0.01% | 1531 |
|
|
2025
Q2 | $7.09M | Sell |
153,200
-86,800
| -36% | -$4.26M | ﹤0.01% | 2845 |
|
|
2025
Q1 | $14.6M | Sell |
240,000
-210,800
| -47% | -$12.3M | ﹤0.01% | 2192 |
|
|
2024
Q4 | $25.5M | Buy |
450,800
+30,300
| +7% | +$1.69M | ﹤0.01% | 1810 |
|
|
2024
Q3 | $21.8M | Buy |
420,500
+150,000
| +55% | +$7.04M | ﹤0.01% | 1917 |
|
|
2024
Q2 | $11.2M | Buy |
270,500
+267,400
| +8,626% | +$12M | ﹤0.01% | 2356 |
|
|
2024
Q1 | $168K | Sell |
3,100
-704,600
| -100% | -$35.9M | ﹤0.01% | 5439 |
|
|
2023
Q4 | $36.3M | Sell |
707,700
-1,056,100
| -60% | -$55.4M | ﹤0.01% | 1406 |
|
|
2023
Q3 | $102M | Buy |
1,763,800
+1,646,100
| +1,399% | +$101M | 0.01% | 812 |
|
|
2023
Q2 | $7.53M | Sell |
117,700
-66,400
| -36% | -$4.45M | ﹤0.01% | 2540 |
|
|
2023
Q1 | $12.8M | Sell |
184,100
-294,100
| -62% | -$20.7M | ﹤0.01% | 2051 |
|
|
2022
Q4 | $34.4M | Sell |
478,200
-7,000
| -1% | -$528K | ﹤0.01% | 1305 |
|
|
2022
Q3 | $34.5M | Buy |
485,200
+320,100
| +194% | +$23.2M | 0.01% | 1240 |
|
|
2022
Q2 | $12.7M | Sell |
165,100
-626,400
| -79% | -$47.7M | ﹤0.01% | 1967 |
|
|
2022
Q1 | $57.8M | Buy |
791,500
+735,800
| +1,321% | +$49.4M | 0.01% | 1088 |
|
|
2021
Q4 | $3.47M | Sell |
55,700
-78,300
| -58% | -$4.59M | ﹤0.01% | 3360 |
|
|
2021
Q3 | $7.93M | Sell |
134,000
-466,000
| -78% | -$30.7M | ﹤0.01% | 2611 |
|
|
2021
Q2 | $40.1M | Buy |
600,000
+336,600
| +128% | +$21.9M | ﹤0.01% | 1329 |
|
|
2021
Q1 | $16.6M | Sell |
263,400
-168,600
| -39% | -$10.5M | ﹤0.01% | 1909 |
|
|
2020
Q4 | $26.8M | Buy |
432,000
+300,000
| +227% | +$18.4M | ﹤0.01% | 1413 |
|
|
2020
Q3 | $7.91M | Sell |
132,000
-125,500
| -49% | -$7.55M | ﹤0.01% | 2217 |
|
|
2020
Q2 | $15.1M | Buy |
257,500
+202,400
| +367% | +$12.1M | ﹤0.01% | 1572 |
|
|
2020
Q1 | $3.07M | Sell |
55,100
-65,000
| -54% | -$3.97M | ﹤0.01% | 2644 |
|
|
2019
Q4 | $7.71M | Sell |
120,100
-466,500
| -80% | -$26.7M | ﹤0.01% | 2342 |
|
|
2019
Q3 | $29.7M | Sell |
586,600
-1,001,500
| -63% | -$47.1M | 0.01% | 1293 |
|
|
2019
Q2 | $71.6M | Buy |
1,588,100
+272,800
| +21% | +$12.7M | 0.01% | 802 |
|
|
2019
Q1 | $62.8M | Buy |
1,315,300
+193,700
| +17% | +$9.65M | 0.01% | 857 |
|
|
2018
Q4 | $58.3M | Buy |
1,121,600
+763,100
| +213% | +$41M | 0.01% | 843 |
|
|
2018
Q3 | $22.3M | Sell |
358,500
-297,100
| -45% | -$17.6M | ﹤0.01% | 1581 |
|
|
2018
Q2 | $36.3M | Sell |
655,600
-1,064,900
| -62% | -$57.5M | 0.01% | 1166 |
|
|
2018
Q1 | $109M | Buy |
1,720,500
+1,332,800
| +344% | +$85.7M | 0.02% | 598 |
|
|
2017
Q4 | $23.8M | Sell |
387,700
-8,300
| -2% | -$519K | 0.01% | 1459 |
|
|
2017
Q3 | $25M | Sell |
396,000
-111,192
| -22% | -$6.49M | 0.01% | 1358 |
|
|
2017
Q2 | $28.3M | Sell |
507,192
-562,334
| -53% | -$30.6M | 0.01% | 1224 |
|
|
2017
Q1 | $58.2M | Sell |
1,069,526
-1,498,474
| -58% | -$82.2M | 0.01% | 866 |
|
|
2016
Q4 | $150M | Sell |
2,568,000
-579,290
| -18% | -$31.7M | 0.04% | 462 |
|
|
2016
Q3 | $170M | Buy |
3,147,290
+3,139,900
| +42,488% | +$202M | 0.04% | 416 |
|
|
2016
Q2 | $544K | Sell |
7,390
-514,610
| -99% | -$36.4M | ﹤0.01% | 3401 |
|
|
2016
Q1 | $33.3M | Buy |
522,000
+252,000
| +93% | +$15.9M | 0.01% | 1023 |
|
|
2015
Q4 | $18.6M | Buy |
270,000
+264,464
| +4,777% | +$17.5M | ﹤0.01% | 1382 |
|
|
2015
Q3 | $327K | Buy |
+5,536
| New | +$351K | ﹤0.01% | 3561 |
|
Other funds holding BMY
VCM
VPM
JP Morgan Chase's BMY Position: Q1 2026 in Review
JP Morgan Chase increased its Bristol-Myers Squibb (BMY) stake by 23% in Q1 2026, buying an estimated $997M and bringing the position to 92,475,194 shares worth $5.52B. The position accounts for 0.35% of the portfolio, ranked #51.
JP Morgan Chase first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.53B in Q2 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- JP Morgan Chase held 92,475,194 shares of Bristol-Myers Squibb worth $5.52B as of Q1 2026.
- JP Morgan Chase bought 17,107,541 Bristol-Myers Squibb shares in Q1 2026, an estimated $997M.
- Bristol-Myers Squibb made up 0.35% of JP Morgan Chase's portfolio in Q1 2026, its #51 holding.
- JP Morgan Chase first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Bristol-Myers Squibb position peaked at $7.53B in Q2 2022.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.